The regenerative and reparative potential of mesenchymal stem cells (MSCs) make them attractive candidates for numerous cell-directed therapies. The variant degree of tissue repair by transplanted MSCs has been assessed in several published reports. There are many gaps in the knowledge of MSC biology and the underlying reasons for their disparate effectiveness in tissue repair. This review examines successful preclinical models of MSC-directed repair, particularly of myocardial repair, in an attempt to shed light into the events dictating MSC therapeutic efficacy. The reparative advantage of genetically altered MSCs will be described. This overview will elucidate possible molecular mechanisms that can influence MSC engraftment, differentiation, self-renewal, and ultimately increase wound repair.
MESENCHYMAL STEM CELL (MSC)
must not express the protein tyrosine phosphatase cluster of differentiation 45 (CD45 − ) or markers of hematopoi-CHARACTERIZATION etic lineages such as B-cells or T-cells [lineage negative (Lin − )]. MSCs must also express the stem cell antigen MSCs are a heterogeneous population of fibroblastoid cells isolated by their ability to form adherent colo-1 (Sca1 + ) as well as the hyaluronic acid cell adhesion molecule, HCAM (CD44 + ). nies (5, 43, 59) . There are variable methodologies for the initial isolation of the MSCs (5,12). Physical dissocia-A large amount of data is available which characterizes human MSCs (17, 48) . The minimal criteria to tion of the starting tissue may or may not be followed by immunodepletion of unwanted cells (79) . MSCs are define human MSCs have been established by the Mesenchymal and Tissue Stem Cell Committee of the expanded in vitro in serum-containing media to attain a characteristic spindle-like shape (12). Although bone International Society for Cellular Therapy. Human MSCs must express CD105, CD73, and CD90, and lack marrow (BM)-derived MSCs will be the focus of this review; reviews concerning MSCs isolated from adipose expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, and human leukocyte antigen (HLA)-DR surface tissue (39) , umbilical cord blood (27, 83) , and fetal tissues (49) are available. Regardless of the source, MSCs molecules (20) . The above description of the isolation, epitope identi-retain the ability to differentiate into distinct mesenchymal lineages, particularly adipogenic, chondrogenic, and fication, and expansion of MSCs points to the fact that there is variability in the definition of MSCs. Variations osteogenic (48, 66) . Table 1 contains a list of cell surface markers that in the biological activities of these cells are present between isolates and passages (19, 25, 34) . The consensus characterize the antigenic phenotype of murine BMderived MSCs; their categories and the appropriate ref-
reached to define human MSCs is addressing this point; however, no such consensus exists for the murine MSC erences are included. To separate the MSCs from any hematopoietic contaminants of the BM, murine MSCs field. Moreover, the description of the nature of MSCs has relied on the in vitro characterization of these cells or MSC-like pericytes has been documented, their role in tissue repair is not understood. Among other things, due to the lack of a definitive antigen in vivo.
it is still unclear whether these tissue resident cells
DO MSCs EXIST IN VIVO WITHOUT TISSUE
migrate to sites of injury or solely secrete factors that CULTURE MANIPULATION?
contribute to wound healing (16) . Because MSCs are isolated by their adherence to tis-MAIN CLINICAL APPLICATIONS sue culture plates, the field debates the existence of MSCs in situ. In an attempt to ensure MSCs were not
The National Library of Health provides information about ongoing clinical trials at http://clinicaltrials.gov purely an in vitro phenomenon, the presence of stem cells within the neural crest of the vertebrate embryo (68) . Currently, there are 73 clinical trials in which bone marrow-derived MSCs are to be administered as therapy that give rise to mesenchymal tissues have been documented. Analysis of a subset of these stem cells has for a variety of human conditions. None of these trials utilize genetically altered MSCs, a technology that demonstrated that they have mesenchymal properties also in vitro. These studies identify the source of MSCs might be of use in the future. Table 2 contains a list of these conditions, the number of trials engaged in the in the developing embryo and several reviews on these are available (21, 36) . Signaling cascades involved in the particular disease, and the method of administration of MSCs. in vivo generation of these neural crest mesenchymal progenitor cells have been identified (9, 33) .
Homing to Sites of Injury In the adult, a hypothesis that equates MSCs to pericytes or vascular-associated mesenchymal cells has been
The data included in Table 2 clearly demonstrate that the primary form of MSC transplantation, in 20 out of proposed (14, 60, 64) . The work of Simmons et al. demonstrated that bone marrow-derived cells isolated by vir-30 conditions (67%), is intravenous. This form of administration takes advantage of the homing capacity tue of their STRO-1 positivity had MSC qualities not depending on their adherence (22, 60) . The STRO-1 + of MSCs. Clinicians are relying on the ability of MSCs to travel through the vasculature and localize within cells were localized to blood vessel walls of human bone marrow sections, thus the perivascular hypothesis (56) .
injured tissue (18, 53, 54) . The effectiveness of homing ability varies between Pericytes were detected in several human tissues (all known sources of MSCs) and when isolated gave rise to published preclinical reports. One explanation for this was delineated by Rombouts et al. by demonstrating that MSCs in vitro (14) . Interestingly, these pericytes expressed several known MSC markers in their native green fluorescent protein (GFP)-tagged murine MSCs lose their homing abilities in a syngeneic mouse model in vivo state (14) . Although proof of endogenous MSCs following prolonged in vitro expansion (51) . Recently, conditions in which the MSCs are expanded have an effect on the expression of CXCR4; 1-day exposure to several groups have shown that regulation of the CXC chemokine receptor 4 (CXCR4) and its ligand, stromal-hypoxia (1% oxygen tension) was sufficient to increase CXCR4 and CX3CR1 mRNA and protein levels enough derived factor 1-α (SDF1-α), play an important role in the motility of human and rodent MSCs (55, 74 only an increase in engraftment from 0.3% to 0.9% (30) . There are other ligands and receptors involved in (Flt-3) ligand, SCF, interleukin-6 (IL-6), hepatocyte growth factor (HGF), and IL-3] resulted in upregulation MSC migration besides the SDF1-α and CXCR4 axis. HGF and its receptor c-met increase the migration abil-of both cell surface and intracellular CXCR4 (55) . Tail vein injection of cytokine-cultured, and thus CXCR4-ity of MSCs in vitro (61) and have been implicated in the recruitment of MSCs to the site of injury (11). expressing, MSCs into sublethatlly irradiated nonobese diabetic/severe combined immunodeficient (NOD/SCID) Human MSCs express the N-formyl peptide receptor (FPR), suggesting they are able to migrate to inflamma-mice increased the homing to the bone marrow by sevenfold, albeit an increase in detection from 0.03% to tory sites where N-formylated peptides are present in the same way immune cells home to injury (72) .
0.2% of the injected cells only 24 h posttransplant (55). This indicates that even in optimized conditions the effi-
Migrating to the site of injury is only part of the challenge MSCs face for clinical application. MSCs must be cacy of targeting is far less than 1%. The in vitro culture data are exciting, it is important to note that this study had a relatively small sample size (n = 53), a follow-up Type I collagen is the dominant extracellular matrix molecule found in mammalian tissues (62) and so MSCs time of only 6 months, and is the first to show an overall statistical improvement in heart function in all MSC-must be capable of proteolytic degradation of this component to invade and extravasate into the tissue. The treated patients (global symptom score p = 0.027).
Because the available clinical data are scarce, many membrane-tethered 1 matrix metalloproteinase (MT1-MMP) has been recently shown to be involved in human investigators are trying to dissect the necessary events, and the molecular mechanism that drive them, for MSCs MSC trafficking, in vitro and in vivo (38) . MSCs were able to traverse type I collagen matrices 2D and 3D in to positively affect the heart following MI. vitro systems, and this activity was blocked completely POSSIBLE MECHANISMS by siRNA silencing of MT1-MMP. The chick chorioal-OF MSC-MEDIATED REPAIR lantoic membrane (CAM) was used to confirm these results in vivo. Within 2 days of their placing on top of Figure 1 shows the possible results of the transthe membrane, hMSCs invaded the CAM surface and planted cells within the site of injury. Regardless of were detected in the underlying stroma; MT1-MMP whether the mechanism of repair reflects their differentisilencing abrogated their invasive capabilities (38) .
ation (direct contribution) or paracrine effects, the MSCs Understanding the genes/proteins involved in MSC must be able to successfully reach the wound, survive, homing, and their ability to remodel the collagenous and expand within it. This section will focus on the extracellular matrix, will ultimately help increase their molecular mechanisms thought to be involved in these therapeutic efficiency. The CXCR4/SDF1-α signaling events by looking at the effects of genetically altered components seem to be important in the recruitment of MSCs in preclinical models of myocardial repair. MSCs. MT1-MMP seems involved in the degradation and penetration of type I collagen tissue barriers. Further Cardiogenic Differentiation of MSCs Within work is needed to elucidate the regulation of the "hom-Infarcted Myocardium ing" signature necessary for improved migration, inva-As early as 1999, researchers noticed that MSCs sion, and extravasation of MSCs into targeted tissues. could be differentiated in vitro (by 5-azacytidine treatment) into beating, myocyte enhancer factor 2A (MEF-Immunomodulatory Properties 2A)-and MEF-2D-expressing cardiomyocytes (40) . The majority of the current clinical trials (44%) are
More recent work has demonstrated that these cells utilizing MSCs for their immunomodulatory properties.
express functional adrenergic and muscarinic (β 1 , β 2 , M 1 , In conditions like graft versus host disease, Crohn's and M 2 ) receptors after 5-azacytidine treatment in vitro disease, primary Sjogren's syndrome, organ transplan-(24). Instead of using this potentially toxic inhibitor of tation/rejection, systemic sclerosis, type 1 diabetes, DNA methylation to derive cardiomyocytes from MSCs, systemic lupus erythematosus, multiple sclerosis, neuro-Behfar et al. developed a "cardiogenic cocktail" (6). blastoma, and nonmalignant red blood cell disorders, This mix of trophic factors include transforming growth MSCs are being transplanted as treatment by themselves factor-β1 (TGF-β1), bone morphogenetic protein 2 or as adjunct therapy. The biology behind the effects of (BMP2), insulin-like growth factor (IGF1), fibroblast MSCs on the immune system has been explored in sevgrowth factor 4 (FGF4), IL-6, leukemia inhibitory factor eral experimental models. A wide range of immune-(LIF), α-thrombin, vascular endothelial growth factor A suppressant factors have been shown to be secreted by (VEGF-A), tumor necrosis factor-α (TNF-α), and reti-MSCs; information on these and their function can be noic acid. The cocktail was able to drive the nuclear found in several recent reviews (57,65,73,80) and will expression of cardiac NK2 transcription factor related, not be addressed in this review.
locus
[Nkx2.5] and MEF-2C, providing insight into the Myocardial Infarction (MI) Therapy
The second most common application for MSCs in the clinic is treatment for ventricular dysfunction and myocardial repair (70) . Although 10 current trials are under way utilizing MSCs in the setting of MI, very little clinical data have been gathered. A private company, Osiris Therapeutics, recently published clinical results demonstrating that MSC transplantation proved a safe therapy with increased benefits (increased left ventricular ejection fraction and reversed remodeling) compared to the placebo-treated group (26) . Although these molecular mechanisms and signaling pathways that gov-Erythropoietin (Epo) is involved in neovascularization of damaged tissue (28,71) and thus increased vascu-ern MSC cardiogenic differentiation (6). This in vitro phenomenon suggested MSCs could be a novel therapy used lar density was observed in the infarcted hearts treated with Epo-overexpressing MSCs (13) . Without data to to regenerate damaged cardiac tissue and it prompted investigators to look for the in vivo differentiation of indicate endothelial transdifferentiation of MSCs, the authors conclude the MSCs were accessory to the newly MSCs into cardiomyocytes following their administration.
GFP-tagged Lin − c-kit + MSCs injected into the peri-formed blood vessels. The secretion of trophic factors, especially Epo, was what ultimately improved cardiac infarct area following coronary artery ligation were fully incorporated into the myocardium and seemed to give function post-MI. rise to new, regenerated tissue after only 9 days (46) .
Increased Myocardial Survival in Response These results seem unique as several studies of this to the MSC Secretome nature revealed that the level of in vivo cardiogenic differentiation of MSCs is very low (32, 53) 
or completely
The MSC-secreted factors seem to have more than just proangiogenic effects; MSC treatment reduces the lacking (13) . Instead of MSC-derived regeneration of the heart, researchers have shown a fusion event of apoptotic index within the peri-infarct area (37, 68) . In vitro, cultured cardiomyocytes have improved survival MSCs with injured cardiomyocytes (4).
Despite the low levels of direct contribution of the in hypoxic conditions when treated with MSC-CM (31) or in coculture experiments (15, 68, 76) . An important MSCs to the myocardium, MSCs have a positive effect in the function and remodeling of injured myocardium prosurvival factor, Akt, has been shown to be expressed by MSCs in response to hypoxia (68) . Overexpression (31,52), albeit to varying degrees. It is widely accepted that the most probable effect of the MSCs in the site of of Akt in MSCs (Akt-MSCs) increased their survival compared to control but, importantly, injection of their injury is to supply the wound with soluble factors that enhance the repair process.
MSC-CM to the myocardium following MI had a significantly positive effect on the apoptotic index of the Secreted Factors Involved in Cardiac Reperfusion cardiomyocytes (44) .
by MSCs
Microarray analysis performed on the CM obtained from Akt-MSCs documented the presence of secreted An ischemic environment is a direct consequence of coronary artery occlusion (69) . The severity of the frizzled-related protein 2 (sFRP2) (44) . Rat cardiomyocytes in vitro, as well as infarcted mice cardiomyocytes occlusion may lead to myocardial death and necrosis (78) . Neovascularization nourishes the wounded tissue in vivo, had decreased apoptosis when treated with CM from the Akt-MSCs. The prosurvival effect on the cardi-with the necessary nutrients and oxygen supply to prevent further tissue damage and increase repair (58). Sev-omyocytes was due to sFRP2 since CM from "Akt-MSCs minus sFRP2" (knocked down sFRP2 expression eral reports have demonstrated that MSCs induce VEGF expression, and therefore, neovascularization in ische-by siRNA in Akt-MSCs) did not have the same prosurvival effect in either setting. The decrease in cardiomyo-mic myocardium (63, 75, 77, 81) . In vitro analysis of MSC-conditioned media (MSC-CM) demonstrated that cyte apoptosis post-MI due to Akt-MSC-CM led to decreased infarct size (44) . It is important to note that the MSCs themselves secrete a variety of angiogenic factors, among them VEGF and placental growth factor authors looked at infarct size 72 h posttreatment and that they did not assess any functional cardiac parameters. (PlGF); and that these are upregulated in response to hypoxic culture conditions (35) . Together, these studies When heme-oxygenase 1 (HO1) was overexpresseed by MSCs (HO1-MSCs), similar effects as the ones suggest that MSCs may play a role on the reperfusion of the infarcted myocardium.
described above were observed (67) . This group saw significant decrease in the in vitro apoptotic index of the Matsumo et al. reported that the adenoviral overexpression of VEGF by MSCs (VEGF-MSCs) increases HO1-MSCs compared to the control MSCs. In vivo, HO1-MSC-treated infarcted hearts had increased capil-capillary density (approximately twofold) in the VEGF-MSC-treated hearts 28 days post-MI. In this study, the lary density but this was attributed to the increase of VEGF by the HO1-MSCs. Transgene expression led to MSCs were followed by β-galactosidase expression and the number of dual α-smooth muscle actin-and LacZ-a significant decrease in the apoptotic index of cardiomyocytes in the treatment hearts. HO1-MSC treatment positive cells was increased approximately fourfold in the treatment group. These authors suggest that the following MI led to a smaller infarct size, decreased ventricular remodeling, and increased cardiac function transdifferentiation of MSCs to endothelial progeny led to a significant increase in cardiac function and a signifi-28 days post-MI. There was no mention of engraftment or differentiation by the MSCs in this report. The cant decrease in infarct size in the VEGF-MSC-treated group (42).
authors conclude that the most important role of the transgene was its antiapoptotic and antioxidant effects survival advantage also observed in vivo. Although sFRP2-MSCs showed long-term engraftment within on the cardiomyocytes (67) .
infarcted myocardium approximately 2.5-fold greater Enhancing MSC Survival in the Wound than a GFP-MSC control 30 days post-MI (2), the observed degree of engraftment was still modest. The Retroviral expression of the prosurvival gene Akt-1 decreased the apoptotic index of MSCs in vitro (41) . amount of engraftment observed was much greater in another model of tissue repair (2), suggesting engraft-The authors transplanted the Akt-MSCs, or GFP-MSCs as a control, directly onto the rat myocardium following ment also depends on the wound context. Achieving a critical mass of MSCs by improving their survival and MI. Although the transgene expression decreased the apoptosis of the MSCs in vivo, this analysis was per-self-renewal capacity should increase their numbers in the damaged tissue. formed 24 h after the injection. No long-term effect on MSC survival was established. The degree of the incor-CONCLUSION poration of the MSCs into the tissue was not discussed despite observation of MSC-derived cardiomyocytes.
The use of genetically altered MSCs in the context of clinical myocardial repair may be possible in the near Improved cardiac function due to Akt-MSC treatment was determined at 2 weeks post-MI, albeit using an ex future. The safety and effectiveness of genetically altered stem cell therapy have been closely monitored, vivo Langendorff model (41) .
Jiang et al. tested the in vivo efficacy of MSCs trans-particularly in the hematopoietic stem cell (HSC) field. The clinical trials in this field aim to improve the effect duced with a retroviral vector to express both Akt and angiopoietin-1 (Ang-1) (32) . The animals in this study of CD34 + cell treatment for a variety of diseases (i.e., gliobastoma multiforme, severe combined immunodefi-underwent permanent coronary occlusion and were treated with an intramyocardial injection of MSCs.
ciencies, and breast cancer) with overexpression of certain proteins {O-6-methylguanine-DNA methyltransferase Although the authors claim transgene expression afforded the MSC with increased engraftment, these (MGMT[P140K]), adenosine deaminase, and multidrug resistance (MDR1)} (70) . These proteins may increase data were not presented in their publication. Expression of Akt and Ang-1 by MSCs increased blood vessel den-the survival/engraftment of the CD34 + cells as is the case for MGMT[P140K] (50) and MDR1 (45) , or pro-sity within the peri-infarct area and led to a statistical increase in heart function (fractional shortening and vide a missing enzyme to the patient (adenosine deaminase) (8). Information gained from these trials includes ejection fraction) compared to the control media treatment group.
the transduction efficiency utilizing different types of vectors including retroviral (1) and lentiviral (23), to try Retroviral overexpression of Epo by MSCs increased the survival both in vitro and in vivo in a murine subcu-to establish a cutoff for clinical effectiveness. The safety of these vectors has been assessed whereby integration taneous implantation model of Matrigel-embedded MSCs (13) . Although assessment of the Epo-MSC-and sites showed modest dysregulation of surrounding genes (10) . However, potential risks of transduced stem cell control MSC-treated hearts 7 and 14 days post-MI did not demonstrate an increase in MSC engraftment or in transplant still remain. Although there is a long history of trials utilizing the MSC-derived cardiac progeny, there was improved cardiac function related with Epo-MSC treatment.
genetically altered CD34 + cells, this technology remains relatively unexploited and its application in the MSC Improving MSC Self-Renewal field is tentative at best. An alternative approach to the transduction of MSCs prior to administration is sug-Whether MSCs work by direct regeneration or through paracrine modulation, MSCs are unable to have gested by a recent report. An overall improvement in the repair of chronic myocardial infarction with what was a significant effect on the repair process unless a critical mass is attained within the wound (i.e., enhanced termed "guided cardiopoiesis" of the MSCs was demonstrated (7). In this report the authors directed hMSCs engraftment). The levels of engraftment of MSCs in preclinical models of myocardial repair are low (30, 53, 55) .
into cardiopoiesis in vitro with the use of a cardiogenic cocktail prior to in vivo administration in a murine Few clinical data on the engraftment of MSCs are available that address long-term engraftment. In one exam-model of myocardial infarction. Not only were there were no deleterious effects, the "guided" MSCs improved ple, fewer than 1% donor cells were detected 4-6 weeks postinfusion on osteogenesis imperfecta patients (29) .
heart function more compared to control (7). In vitro priming might be an avenue to consider in the clinic. Recently, our group demonstrated that retroviral overexpression of sFRP2 by MSCs (sFRP2-MSCs) increased This review described the mechanisms by which MSCs are thought to increase repair by looking closely the in vitro proliferation (2) and survival of MSCs by modulation of both the BMP and Wnt signaling cas-at their effects on myocardial repair. The involvement of several genes on the ability of the MSCs to home to cades (3). This phenomenon provided the MSCs with a Bartunek, J.; Terzic, A. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal
